Clinical Trials Logo

Clinical Trial Summary

This is a 5-week, multi-center, open-label, dose optimization trial in subjects aged 12-17 years with 22q11DS who have a diagnosis of anxiety disorder, and/or ADHD, and/or ASD. Approximately 12 subjects will be initiated, dose optimized, and maintained on NFC-1 over a period of 5 weeks.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT02895906
Study type Interventional
Source Aevi Genomic Medicine
Status Completed
Phase Phase 1
Start date November 28, 2016
Completion date April 20, 2017

See also
  Status Clinical Trial Phase
Completed NCT01781923 - Cognitive Remediation in 22q11DS N/A
Recruiting NCT03284060 - Social Cognition Training and Cognitive Remediation N/A
Recruiting NCT00916955 - Genetic Modifiers for 22q11.2 Syndrome N/A
Active, not recruiting NCT00556530 - Examining Genetic Factors That Affect the Severity of 22q11.2 Deletion Syndrome
Completed NCT02460328 - Resolution of Primary Immune Defect in 22q11.2 Deletion Syndrome N/A